Cormorant Asset Management, L.P. 13F annual report
Cormorant Asset Management, L.P. is an investment fund managing more than $1.72 trillion ran by Neb Obradovic. There are currently 47 companies in Obradovic’s portfolio. The largest investments include Moonlake Immunotherapeutics and Corbus Pharmaceuticals Hldgs, together worth $465 billion.
$1.72 trillion Assets Under Management (AUM)
As of 7th August 2024, Cormorant Asset Management, L.P.’s top holding is 8,494,151 shares of Moonlake Immunotherapeutics currently worth over $373 billion and making up 21.7% of the portfolio value.
In addition, the fund holds 2,025,000 shares of Corbus Pharmaceuticals Hldgs worth $91.6 billion.
The third-largest holding is Arcellx Inc worth $84.2 billion and the next is Vaxcyte worth $83.1 billion, with 1,100,000 shares owned.
Currently, Cormorant Asset Management, L.P.'s portfolio is worth at least $1.72 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Cormorant Asset Management, L.P.
The Cormorant Asset Management, L.P. office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Neb Obradovic serves as the CCO at Cormorant Asset Management, L.P..
Recent trades
In the most recent 13F filing, Cormorant Asset Management, L.P. revealed that it had opened a new position in
Rapport Therapeutics Inc and bought 2,940,283 shares worth $68.4 billion.
The investment fund also strengthened its position in Vaxcyte by buying
415,000 additional shares.
This makes their stake in Vaxcyte total 1,100,000 shares worth $83.1 billion.
Vaxcyte soared 67.9% in the past year.
On the other hand, there are companies that Cormorant Asset Management, L.P. is getting rid of from its portfolio.
Cormorant Asset Management, L.P. closed its position in Alpine Immune Sciences Inc on 14th August 2024.
It sold the previously owned 2,700,000 shares for $107 billion.
Neb Obradovic also disclosed a decreased stake in Arcellx Inc by 0.1%.
This leaves the value of the investment at $84.2 billion and 1,525,000 shares.
One of the largest hedge funds
The two most similar investment funds to Cormorant Asset Management, L.P. are Standard Investments and Novo A/s. They manage $1.72 trillion and $1.72 trillion respectively.
Neb Obradovic investment strategy
Cormorant Asset Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 31.3% of
the total portfolio value.
The fund focuses on investments in the United States as
40.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
4% of the total holdings value.
On the other hand, large-cap stocks make up only 2.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.55 billion.
The complete list of Cormorant Asset Management, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Moonlake Immunotherapeutics |
No change
8,494,151
|
$373,487,819,000 | 21.72% |
| Alpine Immune Sciences Inc |
Closed
2,700,000
|
$107,028,000,000 | |
| Corbus Pharmaceuticals Hldgs |
No change
2,025,000
|
$91,631,250,000 | 5.33% |
| Arcellx Inc |
14.33%
1,525,000
|
$84,164,750,000 | 4.90% |
| Vaxcyte, Inc. |
60.58%
1,100,000
|
$83,061,000,000 | 4.83% |
| Longboard Pharmaceuticals In |
16.78%
2,790,462
|
$75,426,188,000 | 4.39% |
| EyePoint Pharmaceuticals Inc |
20.77%
8,325,000
|
$72,427,500,000 | 4.21% |
| Rapport Therapeutics Inc |
Opened
2,940,283
|
$68,390,983,000 | 3.98% |
| Crinetics Pharmaceuticals In |
17.39%
1,350,000
|
$60,466,500,000 | 3.52% |
| Edgewise Therapeutics Inc |
No change
3,006,534
|
$54,147,677,000 | 3.15% |
| Merus N.V |
17.48%
840,000
|
$49,702,800,000 | 2.89% |
| BridgeBio Pharma Inc |
41.98%
1,858,351
|
$47,072,031,000 | 2.74% |
| Insmed Inc |
17.39%
675,000
|
$45,225,000,000 | 2.63% |
| Newamsterdam Pharma Company |
53.33%
2,300,000
|
$44,183,000,000 | 2.57% |
| Janux Therapeutics Inc |
40.00%
1,050,000
|
$43,984,500,000 | 2.56% |
| Autolus Therapeutics plc |
Closed
6,616,667
|
$42,214,335,000 | |
| ALX Oncology Holdings Inc. |
Closed
3,142,079
|
$35,034,181,000 | |
| Axsome Therapeutics Inc |
Opened
400,000
|
$32,200,000,000 | 1.87% |
| Aerovate Therapeutics Inc |
Closed
1,069,796
|
$31,633,868,000 | |
| Cg Oncology Inc |
21.88%
975,000
|
$30,780,750,000 | 1.79% |
| Helix Acquisition Corp Ii |
No change
2,909,000
|
$29,729,980,000 | 1.73% |
| Marinus Pharmaceuticals Inc |
Closed
3,250,000
|
$29,380,000,000 | |
| Tourmaline Bio Inc |
Closed
1,250,000
|
$28,625,000,000 | |
| Alumis Inc |
Opened
2,147,400
|
$28,560,420,000 | 1.66% |
| Praxis Precision Medicines I |
47.71%
685,000
|
$28,331,600,000 | 1.65% |
| Abivax Sa |
No change
2,130,000
|
$28,158,600,000 | 1.64% |
| Biohaven Ltd |
29.99%
801,963
|
$27,836,136,000 | 1.62% |
| UroGen Pharma Ltd |
Opened
1,650,000
|
$27,687,000,000 | 1.61% |
| Pharvaris N V |
14.32%
1,466,460
|
$27,569,448,000 | 1.60% |
| Apellis Pharmaceuticals Inc |
Closed
400,000
|
$23,512,000,000 | |
| Arcutis Biotherapeutics Inc |
18.82%
2,525,000
|
$23,482,500,000 | 1.37% |
| Sarepta Therapeutics Inc |
Opened
125,000
|
$19,750,000,000 | 1.15% |
| Cullinan Therapeutics Inc |
Opened
1,125,000
|
$19,620,000,000 | 1.14% |
| Rhythm Pharmaceuticals Inc. |
13.64%
475,000
|
$19,503,500,000 | 1.13% |
| Cargo Therapeutics Inc |
No change
1,182,563
|
$19,417,684,000 | 1.13% |
| Cabaletta Bio Inc |
Closed
1,100,000
|
$18,766,000,000 | |
| Astria Therapeutics Inc |
Closed
1,300,000
|
$18,297,500,000 | |
| Y-Mabs Therapeutics Inc |
Opened
1,450,000
|
$17,516,000,000 | 1.02% |
| Avidity Biosciences, Inc. |
Opened
425,000
|
$17,361,250,000 | 1.01% |
| Biomea Fusion Inc |
No change
3,570,872
|
$16,068,924,000 | 0.93% |
| Ventyx Biosciences Inc |
Closed
2,710,000
|
$14,905,000,000 | |
| Nkarta, Inc. |
Closed
1,350,000
|
$14,593,500,000 | |
| Centessa Pharmaceuticals Plc |
186.97%
1,611,600
|
$14,552,748,000 | 0.85% |
| Tarsus Pharmaceuticals, Inc. |
76.63%
500,000
|
$13,590,000,000 | 0.79% |
| Silence Therapeutics plc |
No change
625,000
|
$11,875,000,000 | 0.69% |
| Kyverna Therapeutics Inc |
Closed
440,000
|
$10,929,600,000 | |
| Arrivent Biopharma Inc |
No change
515,000
|
$9,553,250,000 | 0.56% |
| Immuneering Corp |
Closed
3,295,273
|
$9,523,339,000 | |
| Spyre Therapeutics Inc |
Closed
250,000
|
$9,482,500,000 | |
| Engene Holdings Inc |
No change
1,000,000
|
$9,430,000,000 | 0.55% |
| Korro Bio Inc |
49.77%
265,826
|
$9,003,527,000 | 0.52% |
| IDEAYA Biosciences, Inc. |
45.56%
245,000
|
$8,601,950,000 | 0.50% |
| Rocket Pharmaceuticals Inc |
Closed
300,000
|
$8,082,000,000 | |
| Disc Medicine Inc |
Closed
125,000
|
$7,782,500,000 | |
| Gh Research Plc |
No change
593,043
|
$6,914,881,000 | 0.40% |
| Lantheus Holdings Inc |
No change
75,000
|
$6,021,750,000 | 0.35% |
| Stoke Therapeutics, Inc. |
No change
427,163
|
$5,770,972,000 | 0.34% |
| Mersana Therapeutics Inc |
No change
2,600,000
|
$5,226,000,000 | 0.30% |
| BioAtla, Inc. |
Closed
1,170,870
|
$4,027,793,000 | |
| Neurogene Inc |
80.07%
107,344
|
$3,906,248,000 | 0.23% |
| VYNE Therapeutics Inc. |
No change
1,394,336
|
$2,746,842,000 | 0.16% |
| Compass Therapeutics Inc |
63.48%
2,030,823
|
$2,030,823,000 | 0.12% |
| Verve Therapeutics Inc |
No change
350,000
|
$1,708,000,000 | 0.10% |
| RAPT Therapeutics, Inc. |
No change
496,750
|
$1,515,088,000 | 0.09% |
| No transactions found | |||
| Showing first 500 out of 64 holdings | |||
Hedge funds similar to Cormorant Asset Management, L.P.
- Altos Ventures Management
- Soma Equity Partners L.P.
- Darlington Partners Capital Management, L.P.
- Quintet Private Bank (europe) S.A.
- Sageview Advisory
- Novo A/s
- Standard Investments
- Diversify Advisory Services
- Kathmere Capital Management
- Lmcg Investments
- Rbf Capital
- Jana Partners Management, L.P.
- 1st Source Bank
- Csenge Advisory